产品
编 号：F025859
分子式：C18H14O8
分子量：358.3
分子式：C18H14O8
分子量：358.3
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1065559-56-9
产品详情
生物活性：
SMND-309 is a metabolite of salvianolic acid B, and exhibits neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats.
体内研究：
SMND-309 (2.5-10 mg/kg; oral intragastric; once a day; for 4 weeks; male Sprague-Dawley rats) treatment ameliorates liver function and decreases the elevation of serum hyaluronic acid, laminin, procollagen type III levels and hydroxyproline content in liver tissue. SMND-309 also decreases the elevation in the malondialdehyde level and restored the decrease in superoxide dismutase and glutathione peroxidase activities. SMND-309 treatment reduces the liver damage and the liver fibrosis grade. SMND-309 treatment powerfully down-regulated the expression of connective tissue growth factor (CTGF) in serum and liver.Animal Model:Male Sprague-Dawley rats (180-200 g) with carbon tetrachloride
Dosage:2.5 mg/kg, 5 mg/kg and 10 mg/kg
Administration:Oral intragastric; once a day; for 4 weeks
Result:The antifibrotic mechanisms might be associated with its ability to suppress the expression of CTGF as well as scavenge lipid peroxidation products and increase endogenous antioxidant enzyme activity.
SMND-309 is a metabolite of salvianolic acid B, and exhibits neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats.
体内研究：
SMND-309 (2.5-10 mg/kg; oral intragastric; once a day; for 4 weeks; male Sprague-Dawley rats) treatment ameliorates liver function and decreases the elevation of serum hyaluronic acid, laminin, procollagen type III levels and hydroxyproline content in liver tissue. SMND-309 also decreases the elevation in the malondialdehyde level and restored the decrease in superoxide dismutase and glutathione peroxidase activities. SMND-309 treatment reduces the liver damage and the liver fibrosis grade. SMND-309 treatment powerfully down-regulated the expression of connective tissue growth factor (CTGF) in serum and liver.Animal Model:Male Sprague-Dawley rats (180-200 g) with carbon tetrachloride
Dosage:2.5 mg/kg, 5 mg/kg and 10 mg/kg
Administration:Oral intragastric; once a day; for 4 weeks
Result:The antifibrotic mechanisms might be associated with its ability to suppress the expression of CTGF as well as scavenge lipid peroxidation products and increase endogenous antioxidant enzyme activity.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备